16:40:28 EST Fri 20 Nov 2026
Enter Symbol
or Name
USA
CA



HYTN spinout Peptide Development begins trading

2026-11-20 13:56 ET - News Release

See News Release (C-HYTN) HYTN Innovations Inc

Mr. Elliot McKerr of HYTN reports

HYTN INNOVATIONS INC. AND PEPTIDE DEVELOPMENT LABS INC. ANNOUNCE TRADING OF PEPT COMMON SHARES ON THE CANADIAN SECURITIES EXCHANGE

Further to the news release of HYTN Innovations Inc. and Peptide Development Labs Inc., dated Nov. 19, 2026, pursuant to a bulletin issued by the Canadian Securities Exchange on Nov. 19, 2026, Peptide Development has now met all final listing requirements of the CSE. Common shares of Peptide Development will begin trading on the CSE at market open on Nov. 20, 2026.

Arrangement

Under the statutory plan of arrangement involving HYTN and Peptide Development, the shareholders of HYTN received Peptide Development common shares by way of a share exchange, pursuant to which each existing share of HYTN held at 12:01 a.m. on Nov. 17, 2026, was exchanged for one new share of HYTN and 0.0555555555555556 of a Peptide Development common share.

The CSE granted final acceptance of the arrangement on Nov. 19, 2026. Peptide Development common shares will begin trading on the CSE at market open on Nov. 20, 2026.

Share reclassification

As part of the arrangement, HYTN reorganized its authorized share structure effective as at 12:01 a.m. on Nov. 17, 2026. Under the reclassification, HYTN's existing common shares were redesignated as Class A common shares and a new class of Class B common shares was created, having rights, privileges, restrictions and conditions identical to those attaching to HYTN's common shares immediately prior to the reclassification. Each outstanding Class A common share was then exchanged for one Class B common share, the Class A common shares were cancelled and eliminated from HYTN's authorized share structure, and the Class B common shares were redesignated as common shares, being the new HYTN common shares. Following the reclassification, HYTN shareholders hold the same number of common shares of HYTN, in the same proportion, as they held immediately prior to the reclassification.

The arrangement, which included the reclassification, was approved by HYTN shareholders at the annual general and special meeting of HYTN held on Nov. 12, 2026. The record date for the reclassification is Nov. 17, 2026. The new HYTN common shares continue to trade on the CSE under the symbol HYTN with Cusip No. 40443L 20 3 and ISIN CA 40443L 20 3 0, effective Nov. 17, 2026.

Stock symbols

New HYTN common shares trade on the CSE under HYTN's current ticker symbol of HYTN. The Cusip number assigned to the new HYTN common shares is 40443L 20 3 (ISIN CA 40443L 20 3 0).

Peptide Development common shares will trade on the CSE under the ticker symbol PEPT. The Cusip number assigned to the Peptide Development common shares is 713467 10 8 (ISIN CA 713467 10 8 9).

About HYTN Innovations Inc.

HYTN formulates, manufactures, markets and sells premium products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. HYTN's mission is to become the top provider of these products in all federally regulated markets. To achieve this, HYTN focuses on identifying market opportunities and quickly bringing its innovative products to market through its elevated development platform.

About Peptide Development Labs Inc.

Peptide Development is a Canadian pharmaceutical development company focused on advancing investigational peptide-based drug candidates through established regulatory pathways. Peptide Development's mission is to develop peptide candidates that may address defined areas of unmet clinical need within a conventional pharmaceutical framework. To achieve this, Peptide Development focuses on advancing its investigational subcutaneous BPC-157 drug candidate for refractory ligament disorders through GMP-controlled (good manufacturing practice) supply, pharmaceutical quality systems, physician-led access, structured data generation and formal clinical development.

We seek Safe Harbor.

© 2026 Canjex Publishing Ltd. All rights reserved.